The Lymphoma Channel

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company), Morphosys, and Takeda. These supporters have no influence over the production of the content.

Welcome to The Lymphoma Channel

Explore the latest updates in lymphoma, including expert interviews from major international congresses, podcasts and e-learning.

Lymphoma comprises a collection of cancers that develop in the lymphatic system and affects the lymphocytes. Broadly, lymphoma is split into two categories: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

In lymphoma, all parts of the lymphatic system can be affected and the disease can be extranodal. NHL includes all subtypes of lymphoma (except for HL) of which there are more than 60 types – making it the most common type of hematological malignancy. NHL is classified into B-cell and T-cell NHL, depending on which type of lymphocyte is affected.

HL is a rare cancer, accounting for around 0.5–1% of all new cancer cases in the UK and US. Conversely, NHL is the 7th most common cancer in the UK and US. The NIH reports that 86.6% of people diagnosed with HL and 72% of those with NHL survive for 5 years or more (SEER data from 2009–2015).

The risk factors for lymphoma are varied and not fully characterized, including EBV infection (responsible for around half of HL cases), a weakened immune system, previous cancer, age and gender, and genetic and lifestyle factors.

Treatment depends on the type of lymphoma, as well as its location and stage. The main treatments for HL are chemotherapy and radiotherapy, whereas the treatment for NHL can be more varied, including stem cell transplants. Low-grade lymphomas may remain indolent for years, whereas high-grade lymphomas are more aggressive. However, paradoxically, high-grade lymphomas often have better prognosis and are easier to treat.

Recent treatment developments for lymphoma include novel chemotherapy regimens, CAR T-cells, antibody-drug conjugates, checkpoint inhibitors, targeted therapies and proton beam therapy.




EHA 2022
ASCO 2022
Tandem Meetings 2022
BSH 2022
EBMT 2022
CAR-T Meeting 2022


Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter